A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B

Carl J. Fichtenbaum, Matthew German, W. Claiborne Dunagan, Victoria J. Fraser, Gerald Medoff, Jorge Diego, William G. Powderly

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We evaluated an amphotericin treatment strategy on the basis of duration of candidemia and clinical findings. Patients without neutropenia who had uncomplicated candidemia received 200 mg of amphotericin B over 5-7 days if they had had ≤ 1 day of documented positive blood cultures (SC group) or a total of 500 mg of amphotericin B over 14-20 days if they had had >1 day of positive cultures (PC group). The clinical cure rate was 93% (95% confidence interval [CI], 77%-99%; n = 29 episodes) in the SC group, with no relapses (median follow-up, 272 days). The clinical cure rate was 83% (95% CI, 64%- 94%; n = 29 episodes) in the PC group, with 1 relapse (4.2%). The results of this pilot study suggest that patients with candidemia may be stratified into risk groups on the basis of the duration of positive blood cultures and other clinical findings. Decisions about the duration of therapy can be made 4-7 days after initiation of treatment. Carefully selected patients with transient uncomplicated candidemia may be safely treated with a short course of amphotericin B. Further prospective validation of this concept should be undertaken particularly to evaluate the impact on low-frequency late complications (e.g., endophthalmitis).

Original languageEnglish
Pages (from-to)1551-1556
Number of pages6
JournalClinical Infectious Diseases
Volume29
Issue number6
DOIs
StatePublished - Dec 1 1999

Fingerprint

Candidemia
Amphotericin B
Confidence Intervals
Recurrence
Endophthalmitis
Neutropenia
Therapeutics
Blood Culture

ASJC Scopus subject areas

  • Immunology

Cite this

Fichtenbaum, C. J., German, M., Dunagan, W. C., Fraser, V. J., Medoff, G., Diego, J., & Powderly, W. G. (1999). A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B. Clinical Infectious Diseases, 29(6), 1551-1556. https://doi.org/10.1086/313499

A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B. / Fichtenbaum, Carl J.; German, Matthew; Dunagan, W. Claiborne; Fraser, Victoria J.; Medoff, Gerald; Diego, Jorge; Powderly, William G.

In: Clinical Infectious Diseases, Vol. 29, No. 6, 01.12.1999, p. 1551-1556.

Research output: Contribution to journalArticle

Fichtenbaum, CJ, German, M, Dunagan, WC, Fraser, VJ, Medoff, G, Diego, J & Powderly, WG 1999, 'A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B', Clinical Infectious Diseases, vol. 29, no. 6, pp. 1551-1556. https://doi.org/10.1086/313499
Fichtenbaum, Carl J. ; German, Matthew ; Dunagan, W. Claiborne ; Fraser, Victoria J. ; Medoff, Gerald ; Diego, Jorge ; Powderly, William G. / A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B. In: Clinical Infectious Diseases. 1999 ; Vol. 29, No. 6. pp. 1551-1556.
@article{c83fd59160cd460082326f30978de3c9,
title = "A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B",
abstract = "We evaluated an amphotericin treatment strategy on the basis of duration of candidemia and clinical findings. Patients without neutropenia who had uncomplicated candidemia received 200 mg of amphotericin B over 5-7 days if they had had ≤ 1 day of documented positive blood cultures (SC group) or a total of 500 mg of amphotericin B over 14-20 days if they had had >1 day of positive cultures (PC group). The clinical cure rate was 93{\%} (95{\%} confidence interval [CI], 77{\%}-99{\%}; n = 29 episodes) in the SC group, with no relapses (median follow-up, 272 days). The clinical cure rate was 83{\%} (95{\%} CI, 64{\%}- 94{\%}; n = 29 episodes) in the PC group, with 1 relapse (4.2{\%}). The results of this pilot study suggest that patients with candidemia may be stratified into risk groups on the basis of the duration of positive blood cultures and other clinical findings. Decisions about the duration of therapy can be made 4-7 days after initiation of treatment. Carefully selected patients with transient uncomplicated candidemia may be safely treated with a short course of amphotericin B. Further prospective validation of this concept should be undertaken particularly to evaluate the impact on low-frequency late complications (e.g., endophthalmitis).",
author = "Fichtenbaum, {Carl J.} and Matthew German and Dunagan, {W. Claiborne} and Fraser, {Victoria J.} and Gerald Medoff and Jorge Diego and Powderly, {William G.}",
year = "1999",
month = "12",
day = "1",
doi = "10.1086/313499",
language = "English",
volume = "29",
pages = "1551--1556",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B

AU - Fichtenbaum, Carl J.

AU - German, Matthew

AU - Dunagan, W. Claiborne

AU - Fraser, Victoria J.

AU - Medoff, Gerald

AU - Diego, Jorge

AU - Powderly, William G.

PY - 1999/12/1

Y1 - 1999/12/1

N2 - We evaluated an amphotericin treatment strategy on the basis of duration of candidemia and clinical findings. Patients without neutropenia who had uncomplicated candidemia received 200 mg of amphotericin B over 5-7 days if they had had ≤ 1 day of documented positive blood cultures (SC group) or a total of 500 mg of amphotericin B over 14-20 days if they had had >1 day of positive cultures (PC group). The clinical cure rate was 93% (95% confidence interval [CI], 77%-99%; n = 29 episodes) in the SC group, with no relapses (median follow-up, 272 days). The clinical cure rate was 83% (95% CI, 64%- 94%; n = 29 episodes) in the PC group, with 1 relapse (4.2%). The results of this pilot study suggest that patients with candidemia may be stratified into risk groups on the basis of the duration of positive blood cultures and other clinical findings. Decisions about the duration of therapy can be made 4-7 days after initiation of treatment. Carefully selected patients with transient uncomplicated candidemia may be safely treated with a short course of amphotericin B. Further prospective validation of this concept should be undertaken particularly to evaluate the impact on low-frequency late complications (e.g., endophthalmitis).

AB - We evaluated an amphotericin treatment strategy on the basis of duration of candidemia and clinical findings. Patients without neutropenia who had uncomplicated candidemia received 200 mg of amphotericin B over 5-7 days if they had had ≤ 1 day of documented positive blood cultures (SC group) or a total of 500 mg of amphotericin B over 14-20 days if they had had >1 day of positive cultures (PC group). The clinical cure rate was 93% (95% confidence interval [CI], 77%-99%; n = 29 episodes) in the SC group, with no relapses (median follow-up, 272 days). The clinical cure rate was 83% (95% CI, 64%- 94%; n = 29 episodes) in the PC group, with 1 relapse (4.2%). The results of this pilot study suggest that patients with candidemia may be stratified into risk groups on the basis of the duration of positive blood cultures and other clinical findings. Decisions about the duration of therapy can be made 4-7 days after initiation of treatment. Carefully selected patients with transient uncomplicated candidemia may be safely treated with a short course of amphotericin B. Further prospective validation of this concept should be undertaken particularly to evaluate the impact on low-frequency late complications (e.g., endophthalmitis).

UR - http://www.scopus.com/inward/record.url?scp=0033390350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033390350&partnerID=8YFLogxK

U2 - 10.1086/313499

DO - 10.1086/313499

M3 - Article

C2 - 10585811

AN - SCOPUS:0033390350

VL - 29

SP - 1551

EP - 1556

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -